The Washington University trial comes as part of a larger platform study, which hopes to understand whether the disease can ...

Eli Lilly (LLY) is set to announce Q4 earnings results, with analysts expecting positive growth driven by key drugs and new product launches.

Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Eli Lilly (NYSE: LLY) stock was the picture of health on Friday. Shares of the massive American pharmaceutical company rose ...

Novo Nordisk's CagriSema trial raised concerns as patients reported weight loss but significant side effects. Investors ...

Leerink Partners analyst David Risinger maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on January 24 and set a price ...

The first participants in an international clinical trial aimed at preventing Alzheimer’s disease in young adults at high ...

Novo Nordisk's phase 1b/2a clinical trial results revealed that their investigational drug, amycretin, led to an average weight loss of 22% over 36 weeks. This is in contrast to a 2% increase observed ...

Waxing bullish about the effects of Novo Nordisk's latest findings on Eli Lilly sentiment was Bank of America Securities analyst Tim Anderson. On the back of those clinical trial results ...